-
1
-
-
0041926731
-
Fidelity and spatio-temporal control in MAP kinase (ERKs) signaling
-
Pouysségur J., and Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signaling. Eur. J. Biochem. 270 (2003) 3291-3299
-
(2003)
Eur. J. Biochem.
, vol.270
, pp. 3291-3299
-
-
Pouysségur, J.1
Lenormand, P.2
-
3
-
-
0013202857
-
Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs
-
Kohno M., and Pouysségur J. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs. Prog. Cell Cycle Res. 5 (2003) 219-224
-
(2003)
Prog. Cell Cycle Res.
, vol.5
, pp. 219-224
-
-
Kohno, M.1
Pouysségur, J.2
-
4
-
-
10344258041
-
Targeting the mitogen-activated protein kinase cascade to treat cancer
-
Sebolt-Leopold J.S., and Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4 (2004) 937-947
-
(2004)
Nat. Rev. Cancer
, vol.4
, pp. 937-947
-
-
Sebolt-Leopold, J.S.1
Herrera, R.2
-
5
-
-
0033590636
-
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
-
Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., Shimada Y., Ari-i S., Wada H., Fujimoto J., and Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18 (1999) 813-822
-
(1999)
Oncogene
, vol.18
, pp. 813-822
-
-
Hoshino, R.1
Chatani, Y.2
Yamori, T.3
Tsuruo, T.4
Oka, H.5
Yoshida, O.6
Shimada, Y.7
Ari-i, S.8
Wada, H.9
Fujimoto, J.10
Kohno, M.11
-
6
-
-
0032984348
-
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
-
Sebolt-Leopold J.S., Dudley D.T., Herrera R., Van Becelaere K., Wiland A., Gowan R.C., Tecle H., Barrett S.D., Bridges A., Przybranowski S., Leopold W.R., and Saltiel A.R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 5 (1999) 810-816
-
(1999)
Nat. Med.
, vol.5
, pp. 810-816
-
-
Sebolt-Leopold, J.S.1
Dudley, D.T.2
Herrera, R.3
Van Becelaere, K.4
Wiland, A.5
Gowan, R.C.6
Tecle, H.7
Barrett, S.D.8
Bridges, A.9
Przybranowski, S.10
Leopold, W.R.11
Saltiel, A.R.12
-
7
-
-
0141508024
-
Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade
-
Collisson E.A., De A., Suzuki H., Gambhir S.S., and Kolodney M.S. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res. 63 (2003) 5669-5673
-
(2003)
Cancer Res.
, vol.63
, pp. 5669-5673
-
-
Collisson, E.A.1
De, A.2
Suzuki, H.3
Gambhir, S.S.4
Kolodney, M.S.5
-
8
-
-
14844285975
-
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
-
Rinehart J., Adjei A.A., Lorusso P.M., Waterhouse D., Hecht J.R., Natale B.B., Hamid O., Varterasian M., Asbury P., Kaldjian E.P., Gulyas S., Mitchell D.Y., Herrera R., Sebolt-Leopold J.S., and Meyer M.B. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22 (2004) 4456-4462
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 4456-4462
-
-
Rinehart, J.1
Adjei, A.A.2
Lorusso, P.M.3
Waterhouse, D.4
Hecht, J.R.5
Natale, B.B.6
Hamid, O.7
Varterasian, M.8
Asbury, P.9
Kaldjian, E.P.10
Gulyas, S.11
Mitchell, D.Y.12
Herrera, R.13
Sebolt-Leopold, J.S.14
Meyer, M.B.15
-
9
-
-
23944439944
-
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
-
Lorusso P.M., Adjei A.A., Varterasian M., Gadgeel S., Reid J., Mitchell D.Y., Hanson L., DeLuca P., Bruzek L., Piens J., Asbury P., Van Becelaere K., Herrera R., Sebolt-Leopold J., and Meyer M.B. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 23 (2005) 5281-5293
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 5281-5293
-
-
Lorusso, P.M.1
Adjei, A.A.2
Varterasian, M.3
Gadgeel, S.4
Reid, J.5
Mitchell, D.Y.6
Hanson, L.7
DeLuca, P.8
Bruzek, L.9
Piens, J.10
Asbury, P.11
Van Becelaere, K.12
Herrera, R.13
Sebolt-Leopold, J.14
Meyer, M.B.15
-
10
-
-
0035891213
-
Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation
-
Nakamura T., Kanda S., Yamamoto K., Kohno T., Maeda K., Matsuyama T., and Kanetake H. Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation. Oncogene 20 (2001) 7610-7623
-
(2001)
Oncogene
, vol.20
, pp. 7610-7623
-
-
Nakamura, T.1
Kanda, S.2
Yamamoto, K.3
Kohno, T.4
Maeda, K.5
Matsuyama, T.6
Kanetake, H.7
-
11
-
-
23044508993
-
Angiopoietin 1 is mitogenic for cultured endothelial cells
-
Kanda S., Miyata Y., Mochizuki Y., Matsuyama T., and Kanetake H. Angiopoietin 1 is mitogenic for cultured endothelial cells. Cancer Res. 65 (2005) 6820-6827
-
(2005)
Cancer Res.
, vol.65
, pp. 6820-6827
-
-
Kanda, S.1
Miyata, Y.2
Mochizuki, Y.3
Matsuyama, T.4
Kanetake, H.5
-
12
-
-
9644257220
-
Characterization of the MEK5-ERK5 module in human neutrophils and its relationship to ERK1/ERK2 in the chemotactic response
-
Hii C.S., Anson D.S., Costabile M., Mukaro V., Dunning K., and Ferrante A. Characterization of the MEK5-ERK5 module in human neutrophils and its relationship to ERK1/ERK2 in the chemotactic response. J. Biol. Chem. 279 (2004) 49825-49834
-
(2004)
J. Biol. Chem.
, vol.279
, pp. 49825-49834
-
-
Hii, C.S.1
Anson, D.S.2
Costabile, M.3
Mukaro, V.4
Dunning, K.5
Ferrante, A.6
-
13
-
-
18644378618
-
A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040
-
Wang Y., Van Becelaere K., Jiang P., Przybranowski S., Omer C., and Sebolt-Leopold J. A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia 7 (2005) 336-347
-
(2005)
Neoplasia
, vol.7
, pp. 336-347
-
-
Wang, Y.1
Van Becelaere, K.2
Jiang, P.3
Przybranowski, S.4
Omer, C.5
Sebolt-Leopold, J.6
-
14
-
-
0242468891
-
CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)
-
Allen L.F., Sebolt-Leopold J., and Meyer M.B. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol. 30 (2003) 105-116
-
(2003)
Semin. Oncol.
, vol.30
, pp. 105-116
-
-
Allen, L.F.1
Sebolt-Leopold, J.2
Meyer, M.B.3
-
15
-
-
0034722894
-
Development of anticancer drugs targeting the MAP kinase pathway
-
Sebolt-Leopold J.S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19 (2000) 6594-6599
-
(2000)
Oncogene
, vol.19
, pp. 6594-6599
-
-
Sebolt-Leopold, J.S.1
-
16
-
-
33646398593
-
The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer
-
Klein P.J., Schmidt C.M., Wiesenauer C.A., Choi J.N., Gage E.A., Yip-Schneider M.T., Wiebke E.A., Wang Y., Omer C., and Sebolt-Leopold J.S. The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia 8 (2006) 1-8
-
(2006)
Neoplasia
, vol.8
, pp. 1-8
-
-
Klein, P.J.1
Schmidt, C.M.2
Wiesenauer, C.A.3
Choi, J.N.4
Gage, E.A.5
Yip-Schneider, M.T.6
Wiebke, E.A.7
Wang, Y.8
Omer, C.9
Sebolt-Leopold, J.S.10
-
17
-
-
17144458301
-
Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice
-
Pagès G., Guerin S., Grall D., Bonino F., Smith A., Anjuere F., Auberger P., and Pouysségur J. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 286 (1999) 1374-1377
-
(1999)
Science
, vol.286
, pp. 1374-1377
-
-
Pagès, G.1
Guerin, S.2
Grall, D.3
Bonino, F.4
Smith, A.5
Anjuere, F.6
Auberger, P.7
Pouysségur, J.8
-
18
-
-
1842863982
-
Study of MAPK signaling using knockout mice
-
Pagès G., and Pouysségur J. Study of MAPK signaling using knockout mice. Methods Mol. Biol. 250 (2004) 155-166
-
(2004)
Methods Mol. Biol.
, vol.250
, pp. 155-166
-
-
Pagès, G.1
Pouysségur, J.2
|